Principal Investigator
Yantao Tian
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Total Trials
1
As PI
1
Completed
0
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
MIXED(2)
DRUG(1)
Apatinib
1 trial
phase_2
ruijin-hospitalCamrelizumab
1 trial
phase_2
ruijin-hospitalS-1, Oxaliplatin
1 trial
phase_2
ruijin-hospital3 unique interventions2 categories
Analytics
Trial Phases
Phase 21
Trial Status
Other1
Role Distribution
Principal Investigator1
PI Rate100%
Activity Timeline
Clinical Trials (1)
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
PrincipalinvestigatorStart date: 2024-11-21
Research Network
Collaboration Network
2 collaborators·1 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
2 similar investigators found
Anita Scheuber, MD
Nimbus Saturn
1 trials
Shared therapeutic areas:
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Similarity Score30%
Zhenggang Zhu
Ruijin Hospital
5 trials
Shared therapeutic areas:
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Worked with same sponsors:
Ruijin Hospital
Collaborated on 1 trial
Similarity Score14%
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
All 1 trials loaded